JP2006515870A5 - - Google Patents

Download PDF

Info

Publication number
JP2006515870A5
JP2006515870A5 JP2006500369A JP2006500369A JP2006515870A5 JP 2006515870 A5 JP2006515870 A5 JP 2006515870A5 JP 2006500369 A JP2006500369 A JP 2006500369A JP 2006500369 A JP2006500369 A JP 2006500369A JP 2006515870 A5 JP2006515870 A5 JP 2006515870A5
Authority
JP
Japan
Prior art keywords
disease
ophthalmic
vaccine
vaccine according
neuropathy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006500369A
Other languages
English (en)
Japanese (ja)
Other versions
JP5291878B2 (ja
JP2006515870A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2004/000006 external-priority patent/WO2004060265A2/en
Publication of JP2006515870A publication Critical patent/JP2006515870A/ja
Publication of JP2006515870A5 publication Critical patent/JP2006515870A5/ja
Application granted granted Critical
Publication of JP5291878B2 publication Critical patent/JP5291878B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006500369A 2003-01-07 2004-01-06 治療的免疫のためのコポリマー1を含む点眼ワクチン Expired - Fee Related JP5291878B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43831003P 2003-01-07 2003-01-07
US60/438,310 2003-01-07
PCT/IL2004/000006 WO2004060265A2 (en) 2003-01-07 2004-01-06 Eye-drop vaccine containing copolymer 1 for therapeutic immunization

Publications (3)

Publication Number Publication Date
JP2006515870A JP2006515870A (ja) 2006-06-08
JP2006515870A5 true JP2006515870A5 (https=) 2007-03-01
JP5291878B2 JP5291878B2 (ja) 2013-09-18

Family

ID=32713312

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006500369A Expired - Fee Related JP5291878B2 (ja) 2003-01-07 2004-01-06 治療的免疫のためのコポリマー1を含む点眼ワクチン

Country Status (11)

Country Link
US (2) US20070248569A1 (https=)
EP (1) EP1583506B1 (https=)
JP (1) JP5291878B2 (https=)
CN (2) CN102580069B (https=)
AT (1) ATE548045T1 (https=)
AU (1) AU2004203772B2 (https=)
CA (1) CA2512735C (https=)
ES (1) ES2386435T3 (https=)
IL (1) IL169552A (https=)
MX (1) MXPA05007329A (https=)
WO (1) WO2004060265A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2656463C (en) * 2006-06-28 2015-12-01 Yeda Research And Development Co. Ltd. Method of treatment of age-related macular degeneration
US8193147B2 (en) 2007-09-24 2012-06-05 Hadasit Medical Research Services & Development Ltd. Use of copolymer 1 for treatment of muscular dystrophy
EP2326342B1 (en) 2008-08-15 2021-10-06 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using interferon gamma to absorb fluid from the subretinal space
AU2010319559A1 (en) 2009-11-10 2012-05-31 Allegro Pharmaceuticals, Inc. Compositions and methods for inhibiting cellular adhesion or directing diagnostic or therapeutic agents to RGD binding sites
US11673914B2 (en) 2009-11-10 2023-06-13 Allegro Pharmaceuticals, LLC Peptide therapies for reduction of macular thickening
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) * 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
NZ703122A (en) 2010-10-11 2016-06-24 Teva Pharma Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
ES2601892T3 (es) 2011-04-21 2017-02-16 Mapi Pharma Limited Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
KR20140101730A (ko) 2011-10-10 2014-08-20 테바 파마슈티컬 인더스트리즈 리미티드 글라티라머 아세테이트에 대한 임상 반응을 예측하는 데 유용한 단일 뉴클레오티드 다형성
WO2015038891A2 (en) * 2013-09-13 2015-03-19 The Penn State Research Foundation Functional peptide analogs of pedf
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
HUE071047T2 (hu) 2016-08-31 2025-07-28 Mapi Pharma Ltd Glatiramer-acetátot tartalmazó depórendszerek
CN106491614A (zh) * 2016-12-06 2017-03-15 郑州郑先医药科技有限公司 一种用于治疗脊髓损伤的西药组合及用途
WO2018136669A2 (en) * 2017-01-19 2018-07-26 Allegro Phamaceuticals, Inc. Therapeutic and neuroprotective peptides
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
KR102874471B1 (ko) 2018-03-05 2025-10-31 매사추세츠 아이 앤드 이어 인퍼머리 콜로니 자극 인자의 표적화에 의한 녹내장 및 시신경병증 치료법
US20230181458A1 (en) * 2020-04-30 2023-06-15 Jeffrey E. Koziol Micro dosing of viral vaccines

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68927679T2 (de) 1988-10-27 1997-06-26 Univ Minnesota Immunhilfsmittel aus Liposome enthaltend Lymphokin IL -2
ZA93216B (en) 1992-01-17 1993-08-18 Solvay Animal Health Inc Vaccine containing acemannan as an adjuvant.
US5571515A (en) * 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
IL113812A (en) 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US6214791B1 (en) * 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
US6153182A (en) * 1997-12-19 2000-11-28 Uab Research Foundation Lymphotactin as an adjuvant
EP1054880A1 (en) * 1998-02-13 2000-11-29 Autoimmune, Inc. TREATMENT OF MULTIPLE SCLEROSIS USING COP-1 AND Th2-ENHANCING CYTOKINES
US6616925B1 (en) * 1998-04-02 2003-09-09 I.D.M. Immuno-Designed Molecules Combined preparation for the treatment of neoplasic diseases or of infectious diseases
JP2003517452A (ja) * 1999-02-05 2003-05-27 アルク−アベル・アー/エス 新規粘膜デリバリーシステム
PL364983A1 (en) * 1999-08-24 2004-12-27 Teva Pharmaceutical Industries, Ltd. A vaccine composition and method of using the same
PT1248643E (pt) * 2000-01-20 2005-10-31 Yeda Res & Dev Utilizacao de copolimero 1 e peptidos e polipeptidos congeneres e de celulas t tratadas co estes compostos para terapia neuroprotectora
DK1294390T3 (da) 2000-06-07 2006-04-03 Yeda Res & Dev Anvendelse af copolymer 1 og beslægtede peptider og polypeptider og T-celelr behandlet dermed til neurobeskyttelse mod glutamattoksicitet
IL160105A0 (en) * 2001-12-06 2004-06-20 Yeda Res & Dev Vaccine for treatment of motor neurone diseases
CA2540701A1 (en) * 2003-09-29 2005-04-07 Chugai Seiyaku Kabushiki Kaisha Proteins expressed in nk cells
JP4501562B2 (ja) 2004-07-09 2010-07-14 旭硝子株式会社 積層膜付き基材およびその製造方法

Similar Documents

Publication Publication Date Title
JP2006515870A5 (https=)
JP2005502616A5 (https=)
IL169552A (en) Eye-drop vaccine containing copolymer 1 for systemic neuroprotection
CA2451521A1 (en) Use of poly-glu, tyr for neuroprotective therapy
Hohlfeld et al. The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis
Rogers Fractures and dislocations of the cervical spine: an end-result study
CA2806942C (en) Compounds for the treatment/prevention of ocular inflammatory diseases
JP2004507460A5 (https=)
Kolahdouz-Isfahani et al. Clear lens extraction with intraocular lens implantation for hyperopia
JP2020505365A (ja) 治療用および神経保護用ペプチド
JP2008521796A5 (https=)
Gedde et al. Update on aqueous shunts
JP2015514760A5 (https=)
JP2002535334A5 (https=)
DE112015000456T5 (de) Verfahren und Zusammensetzungen zur Verwendung in der Behandlung inflammatorischer und Autoimmun-Krankheiten
CN111760016A (zh) 卡泊芬净在制备神经保护药物中的应用
RU2077293C1 (ru) Способ лечения паралитического косоглазия
Ascenzi et al. The Telencephalon: Basal Ganglia
Goodman et al. Lamellar Keratectomy and Repeat Epikeratoplasty Following Failed Epikeratoplasty
Deep et al. Comparison of the efficacy and safety of bepotastine besilate 1.5% and loteprednol etabonate 0.5% ophthalmic solution in patients of vernal keratoconjunctivitis
HK40020736A (en) Therapeutic and neuroprotective peptides
Hamdi The Copeland intraocular lens: five to ten years later
Cai Efficacy of Dexamethasone implant injection in the treatment of persistent diabetic macular edema
WO2004060266A2 (en) Eye-drop vaccine containing copolymer poly-ye for therapeutic immunization
Schwartz Immune-based Therapies for Glaucoma